Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:…

By C. Hartmann, B. Hentschel, Wolfgang Wick, D. Capper, J. Felsberg, M. Simon, M. Westphal, G. Schackert, R. Meyermann, T. Pietsch and 4 more. Acta Neuropathologica, 2010

798 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/077098f2d79416fa7902e1f4f7ea334a3990c40d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. P. Wen

In Genetics

1. Jill S. Barnholtz-Sloan
2. Q. Ostrom

Citations in the corpus

• Epidemiologic and Molecular Prognostic Review of Glioblastoma (2014, background): “IDH1 mutation, GBM with IDH1mutation, AA without IDH1 mutation and GBM without IDH1 mutation (97, 106).”
• Residual Convolutional Neural Network for Determination of IDH Status in Low- and High-grade Gliomas from MR Imaging (2017, background): “IDH wild-type grade III gliomas may in fact exhibit a worse prognosis than IDHmutant grade IV gliomas (10).”
• High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “Indeed, the survival of IDH-mutated GBM is more favourable than for non-mutated grade III astrocytoma, thus underscoring the strong prognostic value of this finding [10, 12].”